Skip to content
Company Analysis

TherapeuticsMD, Inc. TXMD

A comprehensive view of key metrics, scores, and financial health for TherapeuticsMD, Inc.

Overview of TherapeuticsMD, Inc.

TXMD NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
TherapeuticsMD, Inc. (TXMD), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $1.81, about 0.0% overvalued vs fair value, +42.5% 1Y return, ranked 483/1145 in sector.
Metrics Rev Growth 71.6% ROE -2.1%
USD 1.81
0.56%
(Delayed)
• Vol 90d: 35.6%
52-Week Range
Market Cap
$20.90M
Enterprise Value
$12.48M
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Good
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 76%
Confidence: 88%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.therapeuticsmd.com
HQ Boca Raton, FL
Employees 1
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $1.81

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$3.0M
71.6%%
Gross Profit
$1.8M
35.3%%
R&D Expense
$0
Operating Income (EBIT)
-$4.2M
13%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
0.0%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating TherapeuticsMD, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
42
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Consistent Cash Generation Cash generation is strong and consistent (score 1.00).
  • Cash Generation Consistent Cash generation is consistent (score 1.00), indicating reliable business model.

Key risks

  • ROIC Below WACC or Peers ROIC at 37.8th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 18.8th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
20
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing TXMD's balance between Growth (36.4%), Profitability (32.2%), and Safety (31.4%). Growth 36% Safety 31% Profitability 32%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

55th percentile vs peers
56
Key Signals
Rev Growth YoY 71.6% 94p EPS Growth YoY 74.0% 63p Revenue CAGR 3Y -64.9% 3p
Strengths
  • Rev Growth YoY in top 20% of peers (71.6%, 94th percentile)
  • FCF Margin in top 20% of peers (81.2%, 99th percentile)
  • Gross Profit Margin in top 20% of peers (1.00, 97th percentile)
  • Net Debt/EBITDA in top 20% of peers (-3.21, 85th percentile)
  • Consistently strong margins across 3 metrics
Risks

No significant risks identified for this axis.

Profitability

49th percentile vs peers
49
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
48
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for TherapeuticsMD, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.07
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000